Last edition
News about "CirCLIQ OBI"
Sanofi Secures Japan Approval for Subcutaneous Formulation of Sarclisa
Sanofi’s Sarclisa subcutaneous formulation has been approved in Japan for patients with multiple myeloma. The approval is supported by the Phase 3 IRAKLIA study and marks the second global approval after the EU.
CirCLIQ OBI | 22/06/2026 | By News Bureau
EU Approves Sanofi's Sarclisa SC as First On-Body Injector Cancer Therapy
Sanofi’s Sarclisa subcutaneous has received EU approval as the first anticancer therapy delivered via an On-Body Injector (OBI). Administered through the CirCLIQ OBI, the treatment offers flexible home or outpatient use for multiple myeloma patients while maintaining efficacy across all approved Sarclisa indications and combinations.
CirCLIQ OBI | 09/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy